Home › Funds › Vestal Point Capital, LP › DRUG
Vestal Point Capital, LP position in DRUG
BRIGHT MINDS BIOSCIENCES INC · Health Care
Vestal Point Capital, LP reported holding 545,000 shares of DRUG (BRIGHT MINDS BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$27.2M, representing 0.70% of its reported portfolio and ranking #24 among its reported holdings. Vestal Point Capital, LP has disclosed DRUG holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's DRUG position evolved
Vestal Point Capital, LP first disclosed a stake in DRUG in Q1 2026 at 492,319 shares (US$35.9M). The position peaked in Q2 2026 at 545,000 shares, worth US$38.3M. Across 3 filings, Vestal Point Capital, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 545,000 shares valued at US$27.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 492.32K | $35.92M | New |
| Q2 2026 | 545.00K | $38.26M | Add |
| Q3 2026 | 545.00K | $27.15M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DRUG and 13F data
DRUG (BRIGHT MINDS BIOSCIENCES INC) is a Health Care company. 60 other funds we track also report a position in DRUG — the largest reported positions include Cormorant Asset Management, LP (US$39.9M), BRAIDWELL LP (US$24.1M), Vivo Capital, LLC (US$20.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DRUG
- Cormorant Asset Management, LP 800.00K sh · $39.86M · Q3 2026
- BRAIDWELL LP 483.82K sh · $24.10M · Q3 2026
- Vivo Capital, LLC 417.88K sh · $20.82M · Q3 2026
- MPM BioImpact LLC 195.67K sh · $9.75M · Q3 2026
- GREAT POINT PARTNERS LLC 109.60K sh · $5.46M · Q3 2026
- B Group, Inc. 95.00K sh · $4.73M · Q3 2026
- ACUTA CAPITAL PARTNERS, LLC 93.15K sh · $4.64M · Q3 2026
- Ikarian Capital, LLC 88.95K sh · $4.43M · Q3 2026
- Sio Capital Management, LLC 75.15K sh · $3.74M · Q3 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 48.05K sh · $2.39M · Q3 2026
- Artia Global Partners LP 38.41K sh · $1.91M · Q3 2026
- KVP Capital Advisors, LP 31.81K sh · $1.58M · Q3 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held DRUG?
Vestal Point Capital, LP has disclosed DRUG holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Vestal Point Capital, LP's current position in DRUG?
As of Q3 2026, Vestal Point Capital, LP holds 545.00K shares of DRUG (BRIGHT MINDS BIOSCIENCES INC), valued at $27.15M, representing 0.70% of its reported portfolio and ranking #24.
Has Vestal Point Capital, LP been buying or selling DRUG?
In the latest 13F filing (Q3 2026), Vestal Point Capital, LP held unchanged its position in DRUG. The position peaked in Q2 2026 at 545.00K shares.
Which other funds hold DRUG?
Other major institutional holders of DRUG include Cormorant Asset Management, LP, BRAIDWELL LP, Vivo Capital, LLC, among 60 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.